RT Journal Article
SR Electronic
T1 Preexisting diabetes and COVID-associated hyperglycaemia in patients with COVID-19 pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.17.21255548
DO 10.1101/2021.04.17.21255548
A1 Laurenzi, Andrea
A1 Caretto, Amelia
A1 Molinari, Chiara
A1 Bazzigaluppi, Elena
A1 Brigatti, Cristina
A1 Marzinotto, Ilaria
A1 Mercalli, Alessia
A1 Melzi, Raffaella
A1 Nano, Rita
A1 Tresoldi, Cristina
A1 Landoni, Giovanni
A1 Ciceri, Fabio
A1 Lampasona, Vito
A1 Scavini, Marina
A1 Piemonti, Lorenzo
YR 2021
UL http://medrxiv.org/content/early/2021/05/24/2021.04.17.21255548.abstract
AB Aim The aim of the current study was to compare clinical characteristics, laboratory findings and major outcomes of patients hospitalized for COVID-19 pneumonia with COVID-associated hyperglycaemia or preexisting diabetes.Methods A cohort of 176 adult patients with a diagnosis of pre-existing diabetes (n=112) or COVID-associated hyperglycaemia (n=55) was studied. Clinical outcomes and laboratory findings were analysed according to the presence of the two conditions. The time to viral clearance was assessed during the follow-up after hospital discharge.Result Patients with COVID-associated hyperglycaemia had lower BMI, significantly less comorbidities and higher levels of inflammatory markers and indicators of multi-organ injury than those with preexisting diabetes. No differences between preexisting diabetes and COVID-associated hyperglycaemia were evident for symptoms at admission, humoral response against SARS-CoV-2 or autoantibodies to glutamic acid decarboxylase or interferon alpha-4. COVID-associated hyperglycaemia was independently associated with the risk of adverse clinical outcome defined as ICU admission or death (HR 2.11, 95% CI 1.34-3.31; p=0.001), even after adjustment for age, sex and other selected variables associated with COVID-19 severity. Furthermore, we documented a negative association (HR 0.661, 95% CI 0.43-1.02; p=0.063) between COVID-associated hyperglycaemia and the time to swab negativization.Conclusions The recognition of hyperglycaemia as a specific clinical entity associated with COVID-19 pneumonia is relevant for early and appropriate patient management and close monitoring for the progression of disease severity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04318366Funding StatementThis work was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (COVID-2020-12371617)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of IRCCS San Raffaele Scientific Institute, Milan, Italy. (protocol n 34/int/2020; NCT04318366) and all patients signed a written informed consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSome or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.